RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Striaterminalis, As I understand it (Neuro will correct this if it's wrong) - while Organon owns the global Schizo and Depression rights, they can only commercialize a compound if that compound was included in the original agreement with Cortex (regardless of whether it's a high or low impact). To commercialize a new compound that wasn't part of that agreement, Organon would have to hammer out an updated/modified agreement with Cortex, or risk being sued by Cortex/UCI. Servier is in a similar situation with S-18986, since it wasn't part of the original Servier/Cortex agreement (S-18986 is currently in a large MCI Phase 2).

Likewise, Cortex can develop all the new copounds it wants, but we can't commercialize them globally for Schizo or Depression, or ex-N.America for Neurodegenerative/Anxiety, since those territories are owned by Organon and Servier respectively. Cortex would have to license the new compounds to Organon or Servier for the new compounds to be commercialized in those indications/territories.

The Cortex/UCI cognition use patent is unusually broad, covering ANY compound that works via AMPA upmodulation to improve cognition/memory (that would include any/all AMPA upregulating compounds from Lilly, Glaxo, Boehringer Ingelheim, Sanofi-Aventis, or anyone else). Cortex also has a broad use patent covering Neurotrophin Upregulation (BDNF, NGF, GDNF, etc), and others for Endocrine Modulation, Sexual Dysfunction, and co-use with ACHase inhibitors.